320 related articles for article (PubMed ID: 33569345)
1. Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions.
Porter A; Wong DJ
Front Oncol; 2020; 10():592202. PubMed ID: 33569345
[TBL] [Abstract][Full Text] [Related]
2. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
Jafri S; Yaqub A
Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
[TBL] [Abstract][Full Text] [Related]
3. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.
Al-Jundi M; Thakur S; Gubbi S; Klubo-Gwiezdzinska J
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751138
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
5. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
[TBL] [Abstract][Full Text] [Related]
7. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer.
Yun KM; Cohen EEW
JCO Oncol Pract; 2024 Mar; ():OP2300747. PubMed ID: 38452309
[TBL] [Abstract][Full Text] [Related]
8. Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.
Lorusso L; Cappagli V; Valerio L; Giani C; Viola D; Puleo L; Gambale C; Minaldi E; Campopiano MC; Matrone A; Bottici V; Agate L; Molinaro E; Elisei R
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803747
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy in Thyroid Cancer: State of the Art.
Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies in thyroid cancer: an extensive review of the literature.
Bikas A; Vachhani S; Jensen K; Vasko V; Burman KD
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1299-1313. PubMed ID: 27367142
[TBL] [Abstract][Full Text] [Related]
11. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
[TBL] [Abstract][Full Text] [Related]
12. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
Narayanan S; Colevas AD
Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
[TBL] [Abstract][Full Text] [Related]
13. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
Silaghi H; Lozovanu V; Georgescu CE; Pop C; Nasui BA; Cătoi AF; Silaghi CA
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408830
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
15. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.
de la Fouchardiere C; Oussaid N; Derbel O; Decaussin-Petrucci M; Fondrevelle ME; Wang Q; Bringuier PP; Bournaud-Salinas C; Peix JL; Lifante JC; Giraudet AL; Lopez J; Borson-Chazot F
Target Oncol; 2016 Feb; 11(1):71-82. PubMed ID: 26285789
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.
Aashiq M; Silverman DA; Na'ara S; Takahashi H; Amit M
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31533238
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes.
Roof L; Geiger JL
Cancer Manag Res; 2023; 15():343-350. PubMed ID: 37070083
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Cortas C; Charalambous H
Life (Basel); 2023 Dec; 14(1):. PubMed ID: 38255638
[TBL] [Abstract][Full Text] [Related]
20. Effects and Role of Multikinase Inhibitors in Thyroid Cancer.
Laursen R; Wehland M; Kopp S; Pietsch J; Infanger M; Grosse J; Grimm D
Curr Pharm Des; 2016; 22(39):5915-5926. PubMed ID: 27306093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]